Abstract:Background & Aims: The programmed death-ligand 1 (PD -L1) is a major co -inhibitory checkpoint factor that controls T -cell activities in tumours. PD -L1 is expressed on immune cells and tumour cells. Whether tumour cell -expressed PD -L1 affects tumour cells in an immune cell -independent fashion remains largely elusive. In this study, we investigated the significance of tumour cell -expressed PD -L1 with a focus on downstream signals and changes in lipid metabolism. Methods: Immune -independent functions of PD -L1 in tumour growth were investigated in vitro and in immuno-deficient mice in vivo. The global influence of PD -L1 in targeted/untargeted lipidomic metabolites was studied by comprehensive mass spectrometry -based metabolomic analysis in liver cancer. Effects on lipid metabolism were confirmed by triglyceride and cholesterol assays as well as by Oil Red O staining in liver, pancreatic, breast, and oesophageal squamous cancer. Underlying mechanisms were investigated by real-time quantitative PCR, Western blot analysis, co-immunoprecipitation, pulldown assays, immunofluorescence staining, and RNA sequencing. Results: PD -L1 enhanced the accumulation of triglycerides, cholesterol, and lipid droplets in tumours. PD -L1 influenced targeted/untargeted lipidomic metabolites in hepatoma, including lipid metabolism, glucose metabolism, amino acid metabolism, nucleotide metabolism, and energy metabolism, suggesting that PD -L1 globally modulates the metabolic reprogramming of tumours. Mechanistically, PD -L1 activated epidermal growth factor receptor (EGFR) and/or integrin b4 (ITGB4) by forming a complex of PD-L1/EGFR/ITGB4 in the cell membrane, prior to activating PI3K/mTOR/SREBP1c signalling, leading to reprogramming of lipid metabolism in tumours. Functionally, PD -L1 -mediated lipid metabolism reprogramming supported the tumour growth in vitro and in vivo through EGFR and/or ITGB4 in an immune cell -independent manner. Conclusions: Our findings on lipogenesis and EGFR activation by tumour cell -expressed PD -L1 suggest that, in addition to its immunostimulatory effects, anti -PD -L1 may restrict lipid metabolism and EGFR/ITGB4 signalling in liver cancer therapy. Impact and implications: In this study, we present evidence that PD -L1 drives the reprogramming of lipid metabolism in tumours. PD -L1 forms a complex with epidermal growth factor receptor (EGFR) and ITGB4, activating the PI3K/Akt/mTOR/ SREBP1c signalling pathway and thereby contributing to lipid metabolism in cancer progression. Our findings offer novel insights into the mechanisms by which PD -L1 initiates the reprogramming of lipid metabolism in tumours. From a clinical perspective, the anti -PD -L1 antibody may alleviate resistance to the anti-EGFR antibody cetuximab and inhibit the reprogramming of lipid metabolism in tumours. (c) 2024 The Author(s). Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an open access article under the CC BY -NC -ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Upregulation of programmed death ligand 1 by liver kinase B1 and its implication in programmed death 1 blockade therapy in non-small cell lung cancer

PD-L1 Expression and Its Effect on Clinical Outcomes of EGFR-mutant NSCLC Patients Treated with EGFR-TKIs

Interplay Of Mkp-1 And Nrf2 Drives Tumor Growth And Drug Resistance In Non-Small Cell Lung Cancer

Liver Kinase B1 (LKB1) Regulates Proliferation and Apoptosis of Non-Small Cell Lung Cancer A549 Cells via Targeting ERK Signaling Pathway

The Predictive And Prognostic Effects Of Pd-L1 Expression On Tki Treatment And Survival Of Egfr-Mutant Nsclc A Meta-Analysis

The Combination of Anti-Kir Monoclonal Antibodies with Anti-Pd-1/pd-l1 Monoclonal Antibodies Could Be a Critical Breakthrough in Overcoming Tumor Immune Escape in NSCLC

KEAP1 promotes anti-tumor immunity by inhibiting PD-L1 expression in NSCLC

KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma

Targeting leucine-rich repeat serine/threonine-protein kinase 2 sensitizes pancreatic ductal adenocarcinoma to anti-PD-L1 immunotherapy

Lipid alterations play a role in the integration of PD-1/PD-L1 inhibitors and anlotinib for the treatment of advanced non–small-cell lung cancer

Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer

PD-L1 induces autophagy and primary resistance to EGFR-TKIs in EGFR-mutant lung adenocarcinoma via the MAPK signaling pathway

Abstract 6972: Programmed death-ligand 1 (PD-L1) upregulates c-MET phosphorylation via protein tyrosine phosphatase and contributes to the development of MET amplification in epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer

PARP inhibition induces synthetic lethality and adaptive immunity in LKB1-mutant lung cancer

Tumour Cell-Expressed PD-L1 Reprograms Lipid Metabolism Via EGFR/ITGB4/SREBP1c Signalling in Liver Cancer

CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy

LKB1 Mutations Enhance Radiosensitivity in Non-Small Cell Lung Cancer Cells by Inducing G2/M Cell Cycle Phase Arrest

Hypoxia‐inducible Factor‐1α and Nuclear Factor‐κb Play Important Roles in Regulating Programmed Cell Death Ligand 1 Expression by Epidermal Growth Factor Receptor Mutants in Non‐small‐cell Lung Cancer Cells

Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer

926 Immune Profiling of KEAP1-deficient NSCLC: Development of Therapeutic Strategies to Overcome Resistance to Immunotherapy

Programmed death ligand 1/programmed death 1 immune checkpoint regulate radioresistance non-small-cell lung carcinoma escape from natural killer cell immunotherapy